NASDAQ:EGRX - Eagle Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $51.00
  • Forecasted Upside: -0.43 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$51.22
▼ -1.66 (-3.14%)

This chart shows the closing price for EGRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Eagle Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EGRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EGRX

Analyst Price Target is $51.00
▼ -0.43% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Eagle Pharmaceuticals in the last 3 months. The average price target is $51.00, with a high forecast of $51.00 and a low forecast of $51.00. The average price target represents a -0.43% upside from the last price of $51.22.

This chart shows the closing price for EGRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in Eagle Pharmaceuticals. This rating has held steady since April 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/25/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/23/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/21/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/20/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/20/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/18/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/17/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/1/2021Piper SandlerBoost Price TargetNeutral$48.00 ➝ $51.00Medium
8/9/2021William BlairReiterated RatingOutperformMedium
4/20/2020Cantor FitzgeraldReiterated RatingHold$46.00High
3/25/2020Royal Bank of CanadaReiterated RatingBuy$59.00Medium
3/2/2020Cantor FitzgeraldLower Price TargetNeutral$58.00 ➝ $46.00High
8/11/2019Royal Bank of CanadaReiterated RatingBuy$66.00Low
5/7/2019Cantor FitzgeraldReiterated RatingHold$58.00Low
4/24/2019MizuhoReiterated RatingHold$50.00Low
4/15/2019Cantor FitzgeraldReiterated RatingHold$58.00High
3/22/2019MizuhoBoost Price TargetNeutral ➝ Neutral$40.00 ➝ $41.00High
3/1/2019Royal Bank of CanadaSet Price TargetBuy$66.00High
2/28/2019Cantor FitzgeraldReiterated RatingHold$58.00Medium
11/7/2018MizuhoLower Price TargetNeutral$52.00Medium
11/2/2018Royal Bank of CanadaSet Price TargetBuy$64.00Medium
11/1/2018Cantor FitzgeraldDowngradeOverweight ➝ NeutralHigh
10/31/2018Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$82.00 ➝ $54.00High
10/30/2018Cantor FitzgeraldSet Price TargetBuy$80.00High
10/3/2018Cantor FitzgeraldSet Price TargetBuy$80.00Low
9/20/2018Cantor FitzgeraldLower Price TargetOverweight ➝ Buy$81.00 ➝ $80.00High
8/24/2018Cantor FitzgeraldSet Price TargetBuy$81.00Low
8/8/2018Royal Bank of CanadaSet Price TargetBuy$84.00Medium
8/7/2018Piper Jaffray CompaniesSet Price TargetBuy$88.00Low
8/7/2018Cantor FitzgeraldSet Price TargetBuy$81.00Low
7/24/2018Piper Jaffray CompaniesSet Price TargetBuy$86.00Low
6/11/2018Cantor FitzgeraldInitiated CoverageOverweight$81.00High
6/11/2018MizuhoUpgradeUnderperform ➝ NeutralLow
5/17/2018MizuhoReiterated RatingUnderperform$54.00Low
5/10/2018MizuhoReiterated RatingSell$40.00Medium
3/21/2018MizuhoReiterated RatingUnderperform ➝ Underperform$37.00 ➝ $40.00Medium
2/26/2018Royal Bank of CanadaSet Price TargetBuy$71.00Medium
2/26/2018MizuhoReiterated RatingSell$37.00High
1/30/2018Piper Jaffray CompaniesReiterated RatingBuy$79.00Medium
11/9/2017Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$81.00 ➝ $75.00N/A
11/8/2017MizuhoReiterated RatingSell$37.00N/A
10/27/2017Piper Jaffray CompaniesReiterated RatingBuy$75.00N/A
9/6/2017MizuhoLower Price TargetUnderperform ➝ Underperform$40.00 ➝ $37.00High
8/9/2017Piper Jaffray CompaniesSet Price TargetBuy$75.00Medium
7/27/2017Royal Bank of CanadaLower Price TargetOutperform ➝ Outperform$94.00 ➝ $81.00Medium
7/27/2017MizuhoLower Price TargetUnderperform ➝ Underperform$57.00 ➝ $40.00Medium
7/25/2017Piper Jaffray CompaniesSet Price TargetBuy$118.00Medium
7/16/2017Royal Bank of CanadaSet Price TargetBuy$94.00Medium
5/25/2017MizuhoLower Price TargetUnderperform$66.00 ➝ $57.00Low
5/9/2017Piper Jaffray CompaniesSet Price TargetOverweight$90.00 ➝ $118.00High
5/9/2017Royal Bank of CanadaBoost Price TargetOutperform ➝ Outperform$86.00 ➝ $94.00High
4/24/2017Royal Bank of CanadaSet Price TargetBuy$86.00Medium
3/17/2017MizuhoReiterated RatingUnderperform$66.00High
3/2/2017Royal Bank of CanadaReiterated RatingOutperform$86.00N/A
2/27/2017MizuhoBoost Price TargetUnderperform$64.00 ➝ $66.00N/A
1/9/2017Royal Bank of CanadaReiterated RatingOutperform$93.00 ➝ $86.00N/A
1/9/2017MizuhoDowngradeNeutral ➝ Underperform$78.00 ➝ $64.00N/A
11/16/2016MizuhoDowngradeBuy ➝ Neutral$78.00N/A
11/14/2016Royal Bank of CanadaReiterated RatingOutperform$93.00N/A
11/3/2016Royal Bank of CanadaReiterated RatingOutperform$80.00 ➝ $93.00N/A
11/3/2016Royal Bank of CanadaBoost Price TargetOutperform$80.00 ➝ $93.00N/A
11/3/2016MizuhoUpgradeNeutral ➝ Buy$62.00 ➝ $78.00N/A
11/2/2016William BlairBoost Price TargetOutperform$83.00 ➝ $97.00N/A
10/26/2016MizuhoLower Price TargetBuy$65.00 ➝ $62.00N/A
10/15/2016Piper Jaffray CompaniesReiterated RatingBuy$91.00N/A
9/22/2016Royal Bank of CanadaReiterated RatingOutperform$78.00 ➝ $80.00N/A
(Data available from 9/16/2016 forward)

News Sentiment Rating

0.58 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/18/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/20/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/19/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/19/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/18/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/18/2021
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/17/2021
  • 5 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/16/2021

Current Sentiment

  • 5 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Eagle Pharmaceuticals logo
Eagle Pharmaceuticals, Inc. is a biotechnology pharmaceutical company, which focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. Its products include RYANODEX, BENDEKA and BELRAPZO. The company was founded by Scott L. Tarriff on January 2, 2007 and is headquartered in Woodcliff Lake, NJ.
Read More

Today's Range

Now: $51.22
Low: $51.18
High: $52.50

50 Day Range

MA: $48.87
Low: $44.11
High: $53.91

52 Week Range

Now: $51.22
Low: $36.48
High: $55.50

Volume

856 shs

Average Volume

115,614 shs

Market Capitalization

$670.83 million

P/E Ratio

37.94

Dividend Yield

N/A

Beta

0.82

Frequently Asked Questions

What sell-side analysts currently cover shares of Eagle Pharmaceuticals?

The following equities research analysts have issued stock ratings on Eagle Pharmaceuticals in the last year: Piper Sandler, William Blair, and Zacks Investment Research.
View the latest analyst ratings for EGRX.

What is the current price target for Eagle Pharmaceuticals?

1 Wall Street analysts have set twelve-month price targets for Eagle Pharmaceuticals in the last year. Their average twelve-month price target is $51.00, suggesting a possible downside of 0.4%. Piper Sandler has the highest price target set, predicting EGRX will reach $51.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $51.00 for Eagle Pharmaceuticals in the next year.
View the latest price targets for EGRX.

What is the current consensus analyst rating for Eagle Pharmaceuticals?

Eagle Pharmaceuticals currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EGRX will outperform the market and that investors should add to their positions of Eagle Pharmaceuticals.
View the latest ratings for EGRX.

What other companies compete with Eagle Pharmaceuticals?

How do I contact Eagle Pharmaceuticals' investor relations team?

Eagle Pharmaceuticals' physical mailing address is 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677. The specialty pharmaceutical company's listed phone number is (201) 326-5300 and its investor relations email address is [email protected] The official website for Eagle Pharmaceuticals is www.eagleus.com.